There are currently 1046 clinical trials in Ann Arbor, Michigan looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Michigan, University of Michigan Comprehensive Cancer Center, University of Michigan Health System and CS Mott Children's Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Longitudinal Observational Study of the Natural History and Management of Patients With HCC
NCT02954094
Recruiting
TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of participants with HCC within academic and community real-world practices in order to assess the safety and effectiveness of the entire spectrum of current and future therapies across diverse populations.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Hepatocellular Cancer
Register for Updates
Lurbinectedin in FET-Fused Tumors
NCT05918640
Recruiting
The purpose of this study is to find out if a drug called lurbinectedin (the "study drug") is safe and effective at treating people with recurrent or relapsed solid tumors, including Ewing sarcoma.
Gender:
All
Ages:
10 years and above
Trial Updated:
06/11/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Ewing Sarcoma, Desmoplastic Small Round Cell Tumor, Pediatric Cancer, Undifferentiated Sarcoma
Register for Updates
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
NCT04965675
Recruiting
To find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
06/10/2024
Locations: Michigan Head Pain and Neurological Institute, Ann Arbor, Michigan
Conditions: Chronic Migraine in Children
Register for Updates
A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis
NCT05213624
Recruiting
This study is open to adults with a type of kidney disease called focal segmental glomerulosclerosis (FSGS). The purpose of this study is to find out whether a medicine called BI 764198 improves the health of the kidneys in people with FSGS. Three different doses of BI 764198 are tested in this study. Participants are put into 4 groups randomly, which means by chance. Three of the groups receive different doses of BI 764198 and one group receives placebo. Participants are in the study for about... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/10/2024
Locations: University of Michigan Health System, Ann Arbor, Michigan
Conditions: Kidney Disease, Chronic
Register for Updates
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine
NCT05216263
Recruiting
Migraine is characterized by attacks of throbbing, moderate or severe headache, often associated with nausea, vomiting, and/or sensitivity to light and/or sound. The study will assess safety and tolerability of atogepant when added to BOTOX, as well as prospectively evaluate the efficacy of add-on atogepant for migraine prevention. Adverse events and change in disease activity will be monitored. Atogepant is an investigational drug being developed to prevent chronic migraine. Approximately 75 a... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/10/2024
Locations: Michigan Headache & Neurological Institute (MHNI) /ID# 241784, Ann Arbor, Michigan
Conditions: Chronic Migraine
Register for Updates
Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer
NCT05364645
Recruiting
This phase II Lung-MAP treatment trial tests whether carboplatin and pemetrexed with or without selpercatinib works to shrink tumors in patients with RET fusion-positive non-small cell lung cancer that is stage IV or has not responded to previous RET directed therapy. Chemotherapy drugs, such as carboplatin and pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Selpercatinib may st... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Saint Joseph Mercy Hospital, Ann Arbor, Michigan
Conditions: Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Register for Updates
Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use
NCT05509400
Recruiting
This study is being conducted to evaluate the efficacy and tolerability of rimegepant in a population of adults that are unsuitable for triptan medications due to a previous intolerance, lack of efficacy, or contraindication (including a history of clinically-relevant cardiovascular disease).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Michigan Headache & Neurological Institute, Ann Arbor, Michigan
Conditions: Migraine
Register for Updates
Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder
NCT05512377
Recruiting
This study is open to adults with advanced cancer in the biliary tract, pancreas, lung, or bladder. This is a study for people for whom previous treatment was not successful or no treatment exists. The purpose of this study is to find out whether a medicine called BI 907828 helps people with cancer in the biliary tract, pancreas, lung, or bladder. BI 907828 is a so-called MDM2 inhibitor that is being developed to treat cancer. All participants take BI 907828 as a tablet once every 3 weeks. Part... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: University of Michigan Health System, Ann Arbor, Michigan
Conditions: Pancreatic Neoplasms, Solid Tumors, Biliary Tract Cancer, Lung Neoplasms, Bladder Cancer
Register for Updates
Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients
NCT03876769
Recruiting
This is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in de novo HR pediatric and young adult B-ALL patients who received first-line treatment and are EOC MRD positive. The study will have the following sequential phases: screening, pre-treatment, treatment & follow-up, and survival. After tisagenlecleucel infusion, patient will have assessments performed more frequently in the first month and then at Day 29, then every 3 months f... Read More
Gender:
All
Ages:
Between 1 year and 25 years
Trial Updated:
06/10/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: B-Cell Acute Lymphoblastic Leukemia
Register for Updates
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
NCT04234048
Recruiting
This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma, Peripheral T-cell Lymphoma, Peripheral T-Cell Lymphoma, Not Classified, Primary Cutaneous T-cell Lymphoma, Cutaneous T-Cell Lymphoma, Unspecified, Cutaneous T-cell Lymphoma, Follicular T-Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Sézary's Disease, Mycosis Fungoides
Register for Updates
Zenith® Fenestrated+ Clinical Study
NCT04875429
Recruiting
The Zenith® Fenestrated+ Endovascular Graft Clinical Study will assess the safety and effectiveness of the Zenith® Fenestrated+ Endovascular Graft (ZFEN+) in combination with the BeGraft Balloon-Expandable FEVAR Bridging Stent Graft System (BeGraft) and Unibody2 for the treatment of patients with aortic aneurysms involving one or more of the major visceral arteries.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: University of Michigan Health System, Ann Arbor, Michigan
Conditions: Aortic Aneurysm, Abdominal, Juxtarenal Aortic Aneurysm, Extent IV Thoracoabdominal, Pararenal Aneurysm
Register for Updates
Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis
NCT04380740
Recruiting
This is a multicenter randomized, double blind, Phase 2 trial for patients receiving transplants from 7 of 8 HLA matched donors, in which an extended dosing regimen of abatacept, and a short-term dosing regimen + placebo, when added to standard calcineurin inhibitor + methotrexate-based prophylaxis, will be compared for their ability to improve outcomes in patients with a minimum follow-up of one year post-transplant. All patients will receive 4 doses of abatacept (Days -1, +5, +14, +28). Prior... Read More
Gender:
All
Ages:
2 years and above
Trial Updated:
06/10/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Graft Vs Host Disease
Register for Updates